Protext Mobility, Inc. (Txtm) and Rsammda LLC (Delaware) Provides Shareholder Update


Ryan Allway

November 1st, 2022

News, Top News


Companies Announces Significant Initial Order for 2.33 Million Pounds of Genus Cannabis Sativa

 

Wilmington, Delaware | November 01, 2022 02:57 PM Eastern Daylight Time

 

Protext Mobility, Inc. (OTC PINK: TXTM) and RSAMMDA LLC (Delaware) (“RSAMMDA.LLC”) are pleased to provide the following shareholder update and announce an initial order for 2.33 million pounds of Genus Cannabis Sativa under a supply agreement.

 

Dr. Ahmed Jamaloodeen (Dr.J), Protext Chairman commented, “This is a terrific milestone and demonstrates years of hard work and relentless pursuit of educating the masses and government collaboration. The initial order calls for the delivery of 2.33 million pounds of cannabis, arguably the largest single cannabis flower and biomass order in history to date post legalization.

 

The specific strain we are growing for this order is Charlottes Angel for high percentage CBD flower and biomass. Everything we do is under South Africa federally issued permits, and license to import, export, grow hemp and cannabis from seed to sale, R & D, as well as develop and distribute our own brand of finished products.

 

“Our proprietary, branded CBD product line and online marketplace is anticipated to launch shortly. Due to our early pioneering of hemp and cannabis as a massive community uplift opportunity in South Africa, we were approved as the first government sponsored pilot project that would enable proof of concept to other farms as a blueprint of this business model.

 

This early blueprint is now a proven business model for South African farmers, and we are now at the forefront of SA becoming a recognized global leader in hemp and cannabis production. To further these efforts, last week I attended the AFASA AGM conference and gave a presentation to 1000’s of farmers who are now part of the Cannabis Commodity Cluster Formation, which I’ve been appointed as National Cannabis Commodity Chairman – The first in history.” (link to Dr.J Cannabis Expo 2022 presentation discussing SA community uplift and cannabis: youtube.com/DR.J)

 

Dylon Du Plooy, Protext CEO, commented, “The hemp renaissance is well underway, with renewed interest from global industrial companies to find cheaper and greener resources that can be used to produce 1000’s of end product. America is decades behind the sustainable materials revolution. That represents a big opportunity for us to unlock the potential of industrial hemp in the world’s strongest economy, with the lowest cost product available globally. For South Africa, the opportunity is to take a global role in what we believe is the beginning of an industrial hemp renaissance. We can not only produce product at the lowest cost basis on a global basis, but we can monetize the farm with 3 annual grows, making our hemp, biomass, and cannabis much sought after from customers around the world. In fact, this substantial off take agreement for an initial 2.3 million pounds is being delivered to a US customer. Why? Not only for the quality of the product, but our cost basis is so competitive we can deliver product that includes freight shipping cost to US customers, that is lower than they can get anywhere in North America.” #TXTMTribe #TXTMTribeRaok #TXTMRaok.

 

Dr. J continued, “As we have previously discussed, we believe there is significant value in the human capital derived from our knowledge, Government and other relationships, compliance, resources, facilities, biomass, and infrastructure that is invaluable. The Permits we are in possession of allow for Genus Cannabis Sativa import, export, grow & cultivation, research, testing, and end product development for global distribution, all of which are anticipated to be utilized by Protext with the end goal to commercialize the live plant extraction technology and bring superior end products to the global market. Having technology that’s been tested and proven to increased bioavailability by 10-15x is significant and puts us miles ahead of all competitors. Additional testing is anticipated to be conducted with cannabis being grown on the farm right now. The testing will focus on maximizing yield as well as testing various strains of Genus Cannabis Sativa. We will also begin conducting the R&D using the New Age Extraction Technology for other Indigenous Plant Flora with medicinal properties including Psilocybin. We believe that the significance of the implications our live plant Extraction Technology can have on not only our yield, but also on an entire industry with its 10-15X Bioavailability has been over looked due to the complexity of the science. In layman’s terms we stand to produce Natural Plant Based Medicine with 10-15 times more bioavailability than current products on the market, at a fraction of the cost.

 

“As we previously discussed, but worth repeating, we entered into this transaction with Protext as we believe there to be numerous synergies by allowing access to certain assets of our established business’ with Protext as well as commercialize the Protext proprietary live plant extraction technology and processes into our existing Genus Cannabis Sativa infrastructure. Prior to the merger, Protext had collaborated with RSAMMD whereby the companies utilized Protext’s proprietary live plant extraction technology along with Kettle extraction equipment to conduct a series of live cannabis extraction testing at New Castle Farm under permits for Genus Cannabis Sativa, with the goal to produce an emulsion rich with cannabinoid but with little to no conversion of THC-A to psychoactive THC. We undertook a series of tests to prove out that the Kettle system and extraction technologies did what they were supposed to do. As part of our previous investigations, various tests were completed using live cannabis flower and leaf, rendered into liquid emulsions supplied by the farm in New Castle. Prior to now, it was hypothecated that processing live Genus Cannabis Sativa under lower temperatures would yield a rich nano-emulsion of phytocannabinoids while retaining the non-psychoactive precursor acid form (THC-A).

 

Our investigations have conclusively demonstrated that full-spectrum cannabinoids can be extracted using the proprietary Kettle system, with minimal metabolic conversion, paving the way for advancement of medical research using non-psychoactive cannabis. What has also intrigued us are the findings from prior research and clinical trials that have shown that the Kettle system, when applied to other medicinal plants, can create an extract that is significantly more bioavailable (10-15x) than a standard extract. This means that our cannabis extract should be more potent while providing a dose that could potentially last up to 24 hours in the bloodstream, which is in-line with prior clinical results using other medicinal plants.

 

Medically, this opens the door to a line of natural pharmaceuticals derived from cannabis but at a fraction of the price and with potentially superior outcomes. From a business perspective, an increase of bioavailability in that magnitude can be a game changer for cultivators as it essentially could increase the net yield by a factor of 10-15x per plant, per acre, per farm. This initial order is just the beginning and leadership is excited for what’s to come. We will lead the change we want to see in our world” concluded Dr.J.

 

CONTACT INFORMATION

For further information, or inquiries relating to partnerships in SA, JV opportunities and/or off-take/supply agreements please feel free to contact us

 

Dylon Du Plooy at: dylon@rsammd.co.za

Dr.J at: exportintl@aol.com

Follow us at:

https://twitter.com/RSAMMD

https://twitter.com/ProtextP

 

About Protext (OTC PINK: TXTM)

Through its prior acquisitions, Protext has engaged in the research, testing and development of highly bioavailable botanical products all-natural ingredients formulated for nutraceutical and pharmaceutical applications through the use of proprietary live plant extraction technology.

Website: www.protxtm.com

 

About RSAMMDA.LLC:

RSAMMDA.LLC. is a wholly owned subsidiary of TXTM focused on acquisitions with two principals, Mr. Dylon Du Plooy and Dr. Ahmed Jamaloodeen (“Dr. J”). Mr. Du Plooy is a South African pioneer in the research, cultivation, production and distribution of medical cannabis and cannabinoids.

 

Dr. J operates the 5000 Hectare New Castle Farm as well as federally issued hemp permits issued by the Government of South Africa. Together, we partner with leading hospitals and universities globally to advance the clinical benefits and applications of cannabinoids.

 

RSAMMDA.LLC founders are a group of medical doctors and pharmacists, and cannabis activists who have been at the forefront of medical cannabis legislation and South African cannabis legalization, which took place in September 2018. We are committed to the advancement of technology and scientific research that leads to an improved quality of life for patients around the world.

Website: www.rsammda.com

 

Safe Harbor Statement

This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance or guarantee that such expectations and assumptions will prove to have been correct. Forward- looking statements are generally identifiable by the use of words like “may,” “will,” “should,” “could,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” or “project” or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward- looking statements, as these statements are subject to numerous factors and uncertainties, including but not limited to: adverse economic conditions, competition, adverse federal, state and local government regulation, international governmental regulation, inadequate capital, inability to carry out research, development and commercialization plans, loss or retirement of key executives and other specific risks. To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made. The company disclaims any obligation to update information contained in any forward-looking statement. This press release shall not be deemed a general solicitation.

 

Contact Details

Dylon Du Plooy

+27 72 889 2581

dylon@rsammd.co.za

Company Website

https://www.protxtm.com/

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.


Network Partners

Follow Us on Social Media

About CFN Media Group

CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.

Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.

Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer

loading